Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Seres Therapeutics, Inc. - Common Stock (NQ:MCRB)

7.055 +0.100 (+1.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Seres Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
Via Benzinga
Uber To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Earnings Scheduled For May 7, 2025
Via Benzinga
Quest Diagnostics Posts Better-Than-Expected Earnings, Joins Pentair, 3M, Danaher And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Earnings Scheduled For November 13, 2024
Via Benzinga
What's Next: Seres Therapeutics's Earnings Preview
Via Benzinga
Seres Therapeutics's Earnings: A Preview
Via Benzinga
Stay updated with the stocks that are on the move in today's pre-market session.
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Stay updated with the stocks that are on the move in today's after-hours session.
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Earnings Scheduled For March 13, 2025
Via Benzinga
What's going on in today's after hours session
Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
This Verizon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q2 2024
MCRB stock results show that Seres Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q1 2024
MCRB stock results show that Seres Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Nasdaq Down Over 50 Points; Uber Posts Q1 Loss
Via Benzinga
Emerson Electric To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Gold Price Alert: Gold Spot Prices Just Hit a Record High Today
Investors in gold are excited on Tuesday as the spot price of the precious metal hit a recent high of $2,113.28 per ounce during a rally. 
Via InvestorPlace
MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q4 2023
MCRB stock results show that Seres Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Why Is Microbiome-Based Seres Therapeutics Stock Trading Higher Today?
Seres Therapeutics Inc (NASDAQ: MCRB) received FDA Fast Track Designation for SER-155, an investigational oral, cultivated microbiome therapeutic designed to prevent GI-associated bacterial infections... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For March 5, 2024
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.